Loading...
Market
Will Madrigal reduce Rezdiffra prescription fill time to 30 days by end of Q3 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Madrigal Pharmaceuticals' official announcements or reports
Story
Madrigal's Rezdiffra Launches Strongly with $14.6M Sales
Aug 7, 2024, 08:04 PM
Madrigal Pharmaceuticals has reported a successful launch of its new drug, Rezdiffra, which is the first approved treatment for MASH (Metabolic Associated Steatohepatitis). In the second quarter of 2024, Rezdiffra achieved net sales of $14.6 million, exceeding expectations. The company has secured coverage for more than 50% of commercial patients, with less than 5% requiring a liver biopsy. The launch is expected to gain momentum, with plans to reduce the time to fill prescriptions from 60 days to 30 days by the end of the next quarter. Additionally, Madrigal is preparing for potential EMA approval in 2025.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Wegovy more effective • 25%
Rezdiffra more effective • 25%
Both equally effective • 25%
Inconclusive results • 25%
Wegovy leads market • 25%
Rezdiffra leads market • 25%
Both have equal share • 25%
Other drug leads • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Yes • 50%
No • 50%
